Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beyond monoamines: glutamatergic function in mood disorders.

Akira Kugaya1, Gerard Sanacora

  • 1Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.

CNS Spectrums
|January 10, 2006
PubMed
Summary

The traditional monoamine theory for depression has limitations. Emerging research suggests glutamate neurotransmission plays a key role in mood disorders, offering new targets for antidepressant treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using connectome-based predictive models to reveal the systems standardized tests and clinical symptoms are reflecting.

Nature communications·2026
Same author

Lower synaptic density in mood circuitry underlies depression in Parkinson's disease.

Brain communications·2026
Same author

Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial.

The Journal of clinical psychiatry·2026
Same author

The American Society of Clinical Psychopharmacology (ASCP) task force on the deprescribing of psychotropic medications for mood disorders: Delphi expert consensus.

The British journal of psychiatry : the journal of mental science·2026
Same author

Phase 2 Clinical Trial of MK-1942, a Negative Allosteric Modulator of Metabotropic Glutamate Receptor 2, for Treatment-Resistant Depression.

Journal of clinical psychopharmacology·2026
Same author

Comment on Esketamine 5 Years After Approval: Welcome New Data With Continuing Questions.

The American journal of psychiatry·2026

Area of Science:

  • Neuroscience
  • Psychiatry
  • Neurochemistry

Background:

  • The monoamine theory, focusing on serotonin and norepinephrine, has advanced mood disorder understanding but has limitations.
  • Recent evidence implicates glutamate and other amino acid neurotransmitters in the pathophysiology and treatment of mood disorders.
  • Glial cell dysfunction may impair synaptic glutamate removal, contributing to mood disorders.

Purpose of the Study:

  • To explore the role of the glutamatergic system in mood disorders.
  • To propose a hypothetical model of altered glutamatergic function in mood disorders.
  • To investigate the potential antidepressant mechanisms of antiglutamatergic agents.

Main Methods:

  • In vivo magnetic resonance spectroscopy to measure cortical glutamate levels in depressed subjects.

Related Experiment Videos

  • Review of studies on antiglutamatergic agents (e.g., riluzole, lamotrigine) and their antidepressant efficacy.
  • Analysis of the role of glial cells in synaptic glutamate homeostasis.

    • Main Results:

    • Altered cortical glutamate levels were observed in depressed subjects.
    • Antiglutamatergic agents like riluzole and lamotrigine show potential antidepressant effects.
    • Glial cell abnormalities are linked to impaired glutamate regulation in mood disorders.

    Conclusions:

    • The glutamatergic system is significantly involved in the pathophysiology of mood disorders.
    • Antiglutamatergic agents represent a promising therapeutic strategy for depression.
    • Further research into the glutamatergic system may yield novel antidepressant drug targets.